Afya Limited (AFYA) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A highlight strong financial performance with net income and EBITDA growth, debt reduction, and a positive outlook on shareholder returns via a buyback program. Despite a conservative stance on guidance and challenges with medical ticket growth, the company maintains strong operational metrics and strategic initiatives in education and medical segments. The market cap suggests moderate sensitivity to positive news, leading to a positive stock price prediction.
Key Financial Performance
Revenue Revenue for the first half of 2025 was BRL 1,856 million, a 15% increase year-over-year. This growth was driven by a 3.2% increase in the net average ticket for medical courses, maturation of medical seats, and acquisitions of UNIDOM.
Adjusted EBITDA Adjusted EBITDA for the first half of 2025 was BRL 893 million, a 20% increase year-over-year, with an adjusted EBITDA margin of 48.1%, an increase of 220 basis points. This was driven by gross margin expansions in Undergraduate and Continuing Education segments, operational restructuring, and efficiency improvements in selling, general, and administrative expenses.
Net Income Net income for the first half of 2025 was BRL 434 million, a 70% increase year-over-year. This reflects strong operational performance and the impact of new tax legislation aligned with OECD Pillar Two rules.
Basic EPS Basic EPS for the first half of 2025 was BRL 4.69, a 17% increase year-over-year. This was supported by the increase in adjusted EBITDA and operational performance.
Undergraduate Segment Revenue Revenue for the Undergraduate segment grew over 16% year-over-year, totaling BRL 1,642 million. This was driven by a 14% increase in the number of medical students, integration of UNIDOM, and ramp-up of 4 Mais Medicos campuses.
Continuing Education Revenue Revenue for Continuing Education increased 8% year-over-year, reaching BRL 138 million. This includes a 5% increase in B2P revenue and a 42% increase in B2B revenue, despite a 29% decrease in the residency journey.
Medical Practice Solutions Revenue Revenue for Medical Practice Solutions grew over 9% year-over-year, reaching BRL 84 million. This includes a 12% increase in B2P revenue and an 8% decrease in B2B revenue.
Operational Cash Flow Cash flow from operating activities grew 15% year-over-year, totaling BRL 783 million, driven by robust operational performance.
Net Debt Net debt as of the second quarter of 2025 was BRL 1,621 million, a reduction of BRL 194 million compared to the end of 2024. This reflects strong operational performance and disciplined capital allocation.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Undergraduate and Continuing Education segments: Significant revenue growth and gross margin expansion. Undergraduate segment revenue grew over 16%, totaling BRL 1,642 million. Continuing Education revenue increased 8%, reaching BRL 138 million.
Medical Practice Solutions: Revenue grew over 9% year-over-year, reaching BRL 84 million. B2P revenue increased by 12%.
Ecosystem engagement: 302,000 active users, reflecting strong engagement among physicians and medical students.
Medical seats and student growth: Number of approved medical seats increased by 14%, totaling 3,653 seats. Undergraduate medical students grew by 14%, reaching nearly 26,000 students.
Acquisitions: Acquisition of FUNIC added 60 new medical seats. Integration of UNIDOM contributed to growth.
Operational efficiency: Adjusted EBITDA reached BRL 893 million, expanding 20% year-over-year with a margin of 48.1%. Margin expansion driven by cost initiatives and shared service center efficiencies.
Cash flow: Cash flow from operating activities grew 15%, totaling BRL 783 million. Operational cash conversion ratio was 88.8%.
Share repurchase program: Board approved repurchase of up to 4 million Class A shares by December 31, 2026, reflecting commitment to shareholder value and sustainable performance.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Changes: The new tax legislation aligned with OECD Pillar Two rules has impacted net income, though the company has managed to deliver higher value to shareholders despite this.
Operational Restructuring: Ongoing operational restructuring in the Continuing Education and Medical Practice Solutions segments is necessary to improve costs and efficiency, which could pose challenges if not executed effectively.
Revenue Dependency: 86% of revenue comes from medicine programs, indicating a high dependency on a single segment, which could be a risk if market conditions or regulations change.
Decline in Residency Journey Students: The residency journey segment saw a 29% decrease in students year-over-year, which could impact future revenue and growth in this area.
Reduction in Monthly Active Users: Monthly active users in the Medical Practice Solutions segment decreased by 9% compared to the prior year, potentially affecting engagement and revenue.
Economic and Political Landscape: The share repurchase program and capital allocation strategy are aligned with the current economic and political landscape, which could pose risks if conditions worsen.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Afya reaffirms its full-year 2025 guidance, supported by disciplined execution and strong business fundamentals. Revenue for the second quarter of 2025 reached BRL 919 million, reflecting a 14% increase over the same quarter of the prior year. For the 6-month period, revenue was BRL 1,856 million, an increase of 15% over the same period of last year.
Adjusted EBITDA and Margins: Adjusted EBITDA for the second quarter of 2025 increased 17% to BRL 401 million with an adjusted EBITDA margin of 43.6%, marking an increase of 110 basis points compared to the second quarter of 2024. For the 6-month period, adjusted EBITDA was BRL 893 million, an increase of over 20% compared to the same period of the prior year, with adjusted EBITDA margins of 48.1%, an increase of 220 basis points.
Medical Seats and Student Growth: The number of approved medical seats increased 14%, totaling 3,653 seats, including the FUNIC acquisition. The number of medical students grew almost 14% year-over-year, reaching nearly 26,000 students.
Continuing Education Growth: Revenue for Continuing Education rose to BRL 138 million, up from BRL 128 million in the first semester of 2024, representing an 8% growth. This includes a 5% increase in B2P revenue and an impressive 42% increase in B2B.
Medical Practice Solutions Growth: Revenue for the Medical Practice Solutions segment grew over 9% year-over-year, reaching BRL 84 million. Of this, BRL 75 million came from B2P, up 12%, and BRL 9 million from B2B, down 8% compared to the same period of the prior year.
Share Repurchase Program: Afya plans to repurchase up to 4 million Class A shares by December 31, 2026, reflecting a forward-looking capital allocation strategy aligned with the current economic and political landscape.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: Afya's Board of Directors approved a new share repurchase program. The company plans to repurchase up to 4 million Class A shares by December 31, 2026, through open market transactions or privately negotiated deals. This initiative reflects Afya's commitment to creating shareholder value, ensuring sustainable business performance, and demonstrating the strength and robustness of its balance sheet. It aligns with the company's disciplined and forward-looking capital allocation strategy, considering the current economic and political landscape.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the main levers for profitability expansion in the quarter?
A:The main levers include improved efficiency in SG&A expenses through centralization of services in shared services, transformation in Continuing Education and Medical Solutions segments, and operational leverage from maturing campuses like Mais Medicos and UNIDOM. These initiatives have contributed to margin expansion and an all-time high first-half EBITDA margin since 2019.
Q:Why was there no revision to the EBITDA guidance despite strong first-half performance?
A:Management prefers to remain conservative due to seasonality in Continuing Education and uncertainties in the roadmap of the new cohort after September. They are confident in their guidance but chose to maintain the same range as released earlier.
Q:What is the outlook for the tax rate in the second half of the year?
A:The effective tax rate was reduced to 9% in the first half due to recognition of two tax deferred assets. However, the long-term effective tax rate is expected to converge to 15% in line with the OECD's global minimum tax.
Q:What is the competitive outlook for the medical business in the second half?
A:The competition increased due to more medical seats and institutions being approved, while the number of new high school graduates remained constant. The candidate ratio dropped from 7% to 5%, but the company maintained 100% occupancy and plans to continue its pricing policy without discounts.
Q:Why did medical ticket growth lag behind inflation?
A:Although gross tuition increased slightly above inflation, the net effect was below inflation due to higher discounts from FIES, which accounts for 10-15% of the student base in medical programs.
Q:What is the company's approach to the new taxation structure?
A:The company is challenging the new taxation through legal and administrative means. They are questioning its implementation in court and presenting its impact on the PROUNI program to lawmakers. The outcome of these efforts is uncertain.
Q:What is the company's perspective on the M&A environment?
A:The company is focused on acquiring assets with good brands, reputations, and locations at the right price. They see opportunities due to market conditions and judicialization but remain selective.
Q:What is the rationale behind the buyback program?
A:The buyback program, which accounts for about 4% of shares, is seen as a way to enhance shareholder returns and increase EPS. Management is monitoring liquidity to ensure it does not negatively impact trading volume.
Q:Why did the residents' journey revenue drop significantly year-over-year?
A:The drop was due to a low cycle in 2024, which reduced intake in 2023. However, the company has adjusted its approach and expects an increase in volume starting in September.
Q:What are the company's thoughts on the ENAMED exams?
A:The company views ENAMED as an important opportunity in Continuing Education. The required CapEx is marginal as existing assets and learning objectives can be leveraged. It also opens opportunities in both B2C and B2B markets.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer regarding the likelihood of success in challenging the new taxation structure through legal or administrative means, stating that it is hard to define probabilities at this stage.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Alves Banco
BP physician
BRL Medical
BRL ecosystem
BRL increase
BRL margin
BTG Pactual
Banco BTG
Blanco Chief
BofA Securities
Brazil highlight
CEO conference
Campos Alves
Capobianco
Continuing Education
Education segment
FUNIC
Medical Practice
Officer
Practice Solutions
Research Division
SA Research
UNIDOM
Undergrad Continuing
commitment
margin increase
month period
period BRL
revenue BRL
seat portfolio
student addition
value
AFYA Transcript
Afya Limited (AFYA) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call reveals strong financial performance with significant revenue growth, increased net income, and improved operating margins. These positive financial metrics suggest a healthy business outlook. The lack of discussion on operational updates, strategic initiatives, risk, and return may limit the potential upside, but the strong financial results should still lead to a positive stock price movement in the short term.
Afya Limited (AFYA) Q4 2025 Earnings Call Transcript
Positive3-13
Afya's earnings call highlights strong financial performance with a 15% revenue increase, driven by strategic expansions and acquisitions. EBITDA and net income have also risen significantly, indicating operational efficiency. Despite acknowledging potential risks, the company's proactive financial management and growth in key segments suggest a positive outlook. Given the market cap of approximately $1.5 billion, the positive financial results and strategic growth initiatives are likely to result in a moderate stock price increase, placing the sentiment in the 'Positive' category (2% to 8%).
Afya Limited (AFYA) Q3 2025 Earnings Call Transcript
Positive11-12
The earnings call summary indicates strong financial performance with significant revenue and EBITDA growth, increased medical seats, and a share repurchase program. The Q&A session reveals some uncertainties, such as the impact of new tax reforms and unclear guidance for 2026. However, the company's strategic capital allocation and expected tuition growth contribute positively. Given the market cap of approximately $1.5 billion, the positive sentiment is likely to result in a moderate stock price increase in the range of 2% to 8%.
Afya Limited (AFYA) Q2 2025 Earnings Call Transcript
Positive8-13
The earnings call summary and Q&A highlight strong financial performance with net income and EBITDA growth, debt reduction, and a positive outlook on shareholder returns via a buyback program. Despite a conservative stance on guidance and challenges with medical ticket growth, the company maintains strong operational metrics and strategic initiatives in education and medical segments. The market cap suggests moderate sensitivity to positive news, leading to a positive stock price prediction.
AFYA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
